At Calidi Biotherapeutics, we're advancing a series of ready-to-use product candidates. These are grounded in our cutting-edge platform that harnesses allogeneic stem cell technologies combined with viruses engineered to attack cancer, namely the vaccinia virus and adenovirus.
Calidi through the years
The company was founded in 2014, and is based in San Diego, California. Calidi's first patents were filed in 2015, and later awarded to Calidi for coverage in the United States and in key international territories. The patents encompass several patent families foundational to our SuperNova technology, used alone, and in combination with modern immunotherapies such as checkpoint inhibitors.
In 2016, Calidi acquired our wholly owned subsidiary, based in Bernried, Germany, which is a pillar in the company's Research & Development and Process Development activities. In 2021 Calidi exclusively licensed the NeuroNova technology from Northwestern University and the City of Hope. This technology was developed over 15 years, and has shown strong indications of efficacy in published clinical trial results.
Pioneering the Confluence of Science and Immunotherapy
Calidi's extensive stem cell research shows promising implications for treating cancer.
Executive Team
Allan Camaisa
Boris Minev, MD
Stephen Thesing
Wendy Pizarro, Esq.
Tony Kalajian, CPA/MBA
Antonio F. Santidrian, PH.D.
Amish Patel, PH.D.
David Sans Ph.D., MBA
Barbara Haertl, PH.D.
Thomas Herrmann, PH.D.
Medical &Â Scientific Advisors
Karen Aboody, MD
Ewa Carrier, MD
Santosh Kesari, MD/PH.D.
Matt S. Lesniak, MD
Ashok Srivastava, MD/PH.D.
W.K. Alfred Yung, MD
Dmitriy Zamarin, MD/PH.D.
Our pipeline is robust and ever-evolving, driven by our commitment to pioneering breakthroughs in cancer treatment.
Explore PipelineBoard of Directors
Allan Camaisa
James A. Schoeneck
George Ng
Dr. Heehyoung Lee
Scott Leftwich
